Research Topics
| L LeiterSummaryAffiliation: St. Michael's Hospital Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Postprandial glucose regulation: new data and new implicationsLawrence A Leiter
St Michael s Hospital, University of Toronto, Toronto, Canada
Clin Ther 27:S42-56. 2005..However, physicians continue to rely on fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) to guide management...- Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatinL A Leiter
University of Toronto, Toronto, Canada
Can J Cardiol 15:545-55. 1999..To compare cerivastatin with simvastatin in their long term safety and efficacy in reducing low density lipoprotein cholesterol (LDL-C)... - Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibitionLawrence A Leiter
University of Toronto, Ontario, Canada
Am J Hypertens 18:121-8. 2005.... - Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetesL A Leiter
Department of Medicine, University of Toronto, St Michael s Hospital, Toronto, Ontario, Canada
Diabet Med 22:963-72. 2005..Data are accumulating to show that this therapeutic group offers a number of advantages over traditionally employed oral agents, and these data demonstrate the growing importance of thiazolidinediones in Type 2 diabetes management... - The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?Lawrence A Leiter
St Michael s Hospital, University of Toronto, 61 Queen St East 6121, Toronto, Ont, Canada M5C 2T2
Diabetes Res Clin Pract 68:S3-14. 2005..These findings would provide further support for the use of lipid-lowering agents in patients with diabetes... - Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician officesL A Leiter
St Michael s Hospital and University of Toronto, 61 Queen St E, M4V 2L5 Toronto, Ontario, Canada
Diabetes Care 24:1038-43. 2001..To assess the prevalence of undiagnosed diabetes and glucose intolerance in individuals > or =40 years of age who contacted their family physician for routine care... - Low density lipoprotein cholesterol: is lower better?L A Leiter
St Michael s Hospital, Toronto, Canada
Can J Cardiol 16:20A-2A. 2000..The greatest clinical benefits have been associated with the greatest LDL-C reductions, although the incremental benefit is less at lower levels. Ongoing studies will help determine optimal new treatment targets for LDL-C... - Insulin resistanceL Leiter
University of Toronto, St Michael s Hospital, Toronto, Canada
Can J Cardiol 15:20B-22B. 1999..These include dyslipidemia, dysglycemia and hyperinsulinemia. Insulin resistance, the insulin resistance syndrome and atherogenesis are all thought to involve endothelial dysfunction, though in different vascular beds... 
Glucose lowering and cardiovascular disease: what do we know and what should we do?Alice Y Y Cheng
Division of Endocrinology and Metabolism, University of Toronto and Keenan Research Centre in Li Ka Shing Knowledge Institute of St Michael s Hospital, Toronto, Canada
Eur J Cardiovasc Prev Rehabil 17:S25-31. 2010..For the time being, there remains good evidence for targeting A1c <7% for microvascular protection but attempts to lower A1c beyond this must be considered on an individual basis...- From hyperglycemia to the risk of cardiovascular diseaseLawrence A Leiter
Division of Endocrinology and Metabolism, St. Michael's Hospital and Departments of Medicine and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
Rev Cardiovasc Med 7:S3-9. 2006..Finally, there are multiple mechanisms by which hyperglycemia can increase the risk for CVD... - Clinical use of ezetimibeAlice Y Y Cheng
St Michael's Hospital, Toronto, Ontario
Can J Clin Pharmacol 10:21A-5A. 2003.... - Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safetyVladimir Vuksan
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada
Nutr Metab Cardiovasc Dis 18:46-56. 2008.... 
Hypertension in diabetes: a call to actionNorman R C Campbell
Department of Medicine, University of Calgary, Calgary, Canada
Can J Cardiol 25:299-302. 2009..Intensive individualized lifestyle modification is recommended to prevent and treat hypertension, dyslipidemia, dysglycemia and other vascular risks in people with diabetes...- PROVE-IT proved it: lower is better--proLawrence A Leiter
St Michael s Hospital, University of Toronto, Ontario
Can J Cardiol 22:91B-94B. 2006..An aggressive approach to LDL-C lowering, especially in the high-risk patient, seems warranted... - Lipids and diabetes mellitus: a review of therapeutic optionsJeannette M Goguen
St. Michael's Hospital and Department of Medicine, University of Toronto, Ontario, Canada
Curr Med Res Opin 18:s58-74. 2002..An approach to the patient with diabetes mellitus and dyslipidaemia is provided... - Diagnosis of coronary artery disease in the diabetic patientLawrence A Leiter
Division of Endocrinology, St. Michael's Hospital, University of Toronto, Toronto, Ontario
Can J Cardiol 22:7A-8A. 2006 - Diabetes and cardiovascular disease: the role of glycemic controlAlice Y Y Cheng
St Michael s Hospital, 6121 61 Queen Street East, Toronto, Ontario M5C 2T2, Canada
Curr Diab Rep 9:65-72. 2009.... - Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologistLawrence A Leiter
Division of Endocrinology and Metabolism and Cardiology, Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ont, M5C 2T2, Canada
Atheroscler Suppl 7:37-42. 2006..Optimal care of diabetic and cardiac patients requires a multidisciplinary team approach, with key roles for the cardiologist and diabetologist... - Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in CanadaManoela Braga
Keenan Research Center, Li Ka Shing Knowledge Institute at St Michael s Hospital, University of Toronto, ON, Canada
Can J Cardiol 26:297-302. 2010..To evaluate vascular protection treatment patterns and attainment of the 2003 Canadian Diabetes Association's recommended targets in ambulatory patients with type 2 diabetes... - Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)Shaun G Goodman
St Michael s Hospital and University of Toronto, Toronto, Ontario
Can J Cardiol 26:e330-5. 2010..Despite clear guideline recommendations, there is a growing body of evidence that there is suboptimal use of lipid-lowering treatment in Canadians... - Can thiazolidinediones delay disease progression in type 2 diabetes?Lawrence A Leiter
Department of Medicine, University of Toronto, St Michael s Hospital, Toronto, ON, Canada
Curr Med Res Opin 22:1193-201. 2006..Further deterioration of beta-cell function is associated with progression of diabetes and the potential development of microvascular and macrovascular complications... - Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatientsVineet Bhan
Terrence Donnelly Heart Centre, St Michael s Hospital, University of Toronto, Ontario, Canada
Am J Cardiol 106:1270-6. 2010..Our findings underscore the opportunity to optimize the treatment of these high-risk patients... - Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitusBénédicte Fontaine-Bisson
Department of Nutritional Sciences, University of Toronto, Toronto, Canada
Metabolism 56:649-55. 2007..19 +/- 1.24 vs 1.97 +/- 0.90, P = .6). Our findings suggest that the -238G>A and -308G>A polymorphisms of TNF-alpha alter circulating free fatty acids and insulin resistance in obese subjects with type 2 diabetes mellitus... - How to reach LDL targets quickly in patients with diabetes or metabolic syndromeLawrence A Leiter
St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
J Fam Pract 57:661-8. 2008..To investigate whether using an algorithm to select the starting dose of a statin according to baseline and target LDL-cholesterol (LDL-C) values would facilitate achieving lipid targets in patients with diabetes or the metabolic syndrome... - Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapyJennifer L Y Tsang
Terrence Donnelly Heart Centre, Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Am J Cardiol 102:1142-5. 2008.... - Role of renin-angiotensin system blockade in patients with diabetes mellitusManoela F B Braga
Cardiometabolic Risk Initiative, St Michael s Hospital, University of Toronto, Toronto, Ontario Canada
Am J Cardiol 104:835-9. 2009..In conclusion, overwhelming evidence suggests that the RAS plays an important role in the pathogenesis of DM and its associated cardiovascular risks... - Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS studyLawrence A Leiter
Division of Endocrinology and Metabolism, St Michael s Hospital, University of Toronto, Toronto, Canada
Atherosclerosis 194:e154-64. 2007..Rosuvastatin may therefore improve LDL-C goal achievement in high-risk patients with hypercholesterolemia... - Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?David H Fitchett
Canadian Heart Research Centre, Toronto, Ontario
Can J Cardiol 21:85-90. 2005..However, future recommendations may suggest much lower LDL-C targets than those currently recommended... - Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patientsDavid H Fitchett
Division of Cardiology, St Michael s Hospital, Toronto, Ontario
Can J Cardiol 22:835-9. 2006..Furthermore, registry data show that one-half of these patients are not even achieving the current LDL-C target of 2.5 mmol/L. Causes of the care gap are discussed and possible remedies to achieve the new lower targets are suggested... - Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?Gustavo Saposnik
Division of Cardiology, Canadian Heart Research Centre and Terrence Donnelly Heart Centre, University of Toronto, Canada
Stroke 40:1417-24. 2009..We sought to evaluate and compare differences in treatment patterns and the attainment of current guideline-recommended targets in unselected high-risk ambulatory patients with CAD, CVD, or both... - Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trialDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada
JAMA 300:2742-53. 2008..Low-glycemic index diets may improve both glycemic control and cardiovascular risk factors for patients with type 2 diabetes but debate over their effectiveness continues due to trial limitations... - Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart diseaseLawrence A Leiter
St Michael s Hospital and University of Toronto, Toronto, Ontario, Canada
Am J Cardiol 102:1495-501. 2008..Both treatments were generally well tolerated (clinical trial no. NCT00276484)... - Should you put all diabetic patients on statins?Lawrence A Leiter
Division of Endocrinology and Metabolism, St Michael s Hospital, Toronto, Ontario, Canada
J Fam Pract 56:294-300. 2007 - The incretin system and cardiometabolic diseasePaul E Szmitko
Division of General Internal Medicine, St Michael s Hospital, University of Toronto, 30 Bond Street, Toronto, Ontario, Canada
Can J Cardiol 26:87-95. 2010..The influence of incretins on the cardiovascular system beyond the proatherogenic effect of type 2 diabetes will also be discussed... - Missed opportunities for the secondary prevention of cardiovascular disease in CanadaDaniel G Hackam
Department of Medicine, University of Western Ontario, London, Canada
Can J Cardiol 23:1124-30. 2007.... - Contemporary management of dyslipidemia in high-risk patients: targets still not metAndrew T Yan
Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, Toronto, Ontario, Canada
Am J Med 119:676-83. 2006..There remains an important opportunity to improve the quality of care for these high-risk patients... - Metabolic syndrome under fire: weighing in on the truthA Y Cheng
Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Canada
Can J Cardiol 22:379-82. 2006..Therefore, the 'metabolic syndrome' continues to serve a useful clinical purpose to raise awareness among health care professionals and aid in identifying high-risk individuals... - The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive proteinThomas M S Wolever
Department of Nutritional Sciences, University of Toronto, and the Department of Medicine, St Michael s Hospital, Toronto, Ontario, Canada
Am J Clin Nutr 87:114-25. 2008..The optimal source and amount of dietary carbohydrate for managing type 2 diabetes (T2DM) are unknown... - Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic diseaseHwee Teoh
Division of Cardiac Surgery, Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Am J Cardiol 104:798-804. 2009..In conclusion, an algorithm-based statin uptitration/ezetimibe combination regimen is useful to increase LDL cholesterol lowering where statin monotherapy has not achieved target lipid values... - Willingness to pay for inhaled insulin: a contingent valuation approachHamid Sadri
Department of Pharmaceutical Sciences, University of Toronto, Ontario, Canada
Pharmacoeconomics 23:1215-27. 2005..To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin... - How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) RegistryDaniel G Hackam
Division of Clinical Pharmacology and Toxicology, Sunnybrook and Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
Am Heart J 148:1028-33. 2004.... - The effect of strawberries in a cholesterol-lowering dietary portfolioDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada
Metabolism 57:1636-44. 2008..Added fruit may improve the overall utility of diets designed to lower coronary heart disease risk... - Supplemental barley protein and casein similarly affect serum lipids in hypercholesterolemic women and menDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Canada
J Nutr 140:1633-7. 2010..Nevertheless, because no adverse effects were observed on cardiovascular risk factors, barley protein remains an additional option for raising the protein content of the diet... - Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individualsAnamaria Dascalu
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S3E2, Canada
Can J Physiol Pharmacol 85:856-64. 2007..05.) American ginseng decreased postprandial glycemia and insulinemia; however, 40% of the batches did not reduce glycemia with the anticipated magnitude, irrespective of their saponin composition... - Diabetic dyslipidaemia: effective management reduces cardiovascular riskLawrence A Leiter
Departments of Medicine and Nutritional Sciences, University of Toronto, St Michael s Hospital, 61 Queen Street East 6121Q, Toronto, Ontario, Canada M5C 2T2
Atheroscler Suppl 6:37-43. 2005..The availability of more effective statins should help to close this "action gap", in concert with other measures such as initiatives to improve patient compliance... - Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studiesJohn L Sievenpiper
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Canada
J Am Coll Nutr 25:100-7. 2006..057). CONCLUSIONS: Together the studies indicate 2 g KRG-rootlets is sufficient to achieve reproducible reductions in postprandial glycemia. But the longterm sustainability of KRG selected using this approach remains to be tested... - Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetesDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada
Diabetes Care 25:1522-8. 2002..Cohort studies indicate that cereal fiber reduces the risk of diabetes and coronary heart disease (CHD). Therefore, we assessed the effect of wheat bran on glycemic control and CHD risk factors in type 2 diabetes... - Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participantsDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Canada
Am J Clin Nutr 81:380-7. 2005..Newer dietary approaches combining cholesterol-lowering foods may offer another option, but these approaches have not been compared directly with statins in the same persons... - Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive proteinDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada
JAMA 290:502-10. 2003.... - Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemiaDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael's Hospital, Toronto, Ontario, Canada
Am J Clin Nutr 83:582-91. 2006.... - Use of the statins in patients after acute myocardial infarction: does evidence change practice?C A Jackevicius
Pharmacy Department, University Health Network Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
Arch Intern Med 161:183-8. 2001.... - Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trialManoela F B Braga
St Michael s Hospital, University of Toronto, ON, Canada
Atherosclerosis 203:479-82. 2009..Purpose of this study was to determine whether UDCA had potential to be an effective, safe cholesterol-lowering agent in primary type IIa or IIb hypercholesterolemia... - Long-term intake of North American ginseng has no effect on 24-hour blood pressure and renal functionP Mark Stavro
Risk Factor Modification Centre, St Michael's Hospital, Toronto, Ontario, Canada
Hypertension 47:791-6. 2006..Ginseng did not affect serum cystatin C level. Overall, long-term ginseng use had no effect on 24-hour BP and renal function in hypertensive individuals... - PPAR-alpha: therapeutic role in diabetes-related cardiovascular diseaseAlice Y Y Cheng
Division of Endocrinology and Metabolism, St Michael s Hospital, Toronto, Ontario, Canada
Diabetes Obes Metab 10:691-8. 2008..However, their potential role in combination with statin therapy remains to be further elucidated with ongoing studies... - Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: the role of ginsenosidesJohn L Sievenpiper
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, and Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, ON, Canada
J Am Coll Nutr 23:248-58. 2004..04). CONCLUSIONS: Ginseng has variable glycemic effects, in which the PPD:PPT-ginsenoside ratio might be involved. But the low variance explained suggests the involvement of other unmeasured ginsenoside or non-ginsenoside components... - North American ginseng exerts a neutral effect on blood pressure in individuals with hypertensionP Mark Stavro
Risk Factor Modification Centre, St. Michael's Hospital, 61 Queen St E, 6th Floor, Suite 138, Toronto, Ontario, M5C 2T2, Canada
Hypertension 46:406-11. 2005..The findings together suggested that North American ginseng exerts a neutral acute effect on blood pressure in hypertensive individuals... - Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and womenDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada
Am J Clin Nutr 76:365-72. 2002..Many of the benefits of soy have been attributed to soy isoflavones... - A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemiaDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada
Metabolism 51:1596-604. 2002.... - Null and opposing effects of Asian ginseng (Panax ginseng C.A. Meyer) on acute glycemia: results of two acute dose escalation studiesJohn L Sievenpiper
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 6 138-61 Queen Street East, Toronto, Ontario M5C 2T2, Canada
J Am Coll Nutr 22:524-32. 2003..This is in contrast to our findings with American ginseng. One explanation may be the marked ginsenoside differences. Practitioners and consumers should be aware of ginseng's variable effects... - The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemiaDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, Toronto, Ontario, Canada
Metabolism 52:1478-83. 2003..Combining a number of foods and food components in a single dietary portfolio may lower LDL-C similarly to statins and so increase the potential effectiveness of dietary therapy... - Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?Roger S McIntyre
University of Toronto, Department of Psychiatry, Toronto, ON, Canada
Expert Opin Pharmacother 8:1615-28. 2007..Extant data provide the basis for formulating a hypothesis that TZDs may be salutary for cognitive deficits and several aspects of somatic health (e.g., cardiovascular disease) associated with mood disorders... - Nutritional considerations for older adults with type 2 diabetesAndrea R Josse
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital and Department of Nutritional Sciences, Faculty of Medicine, University of Tornoto, 150 College Street, Toronto, Ontario, Canada
J Nutr Elder 27:363-80. 2008.... - Statin therapy and the management of acute coronary syndromesAnatoly Langer
Canadian Heart Research Centre and St Michael s Hospital, University of Toronto, Toronto, Canada
Can J Cardiol 19:921-7. 2003.... - Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrationsBénédicte Fontaine-Bisson
Department of Nutritional Sciences and Nutrition, University of Toronto, Toronto, Canada
Am J Clin Nutr 86:768-74. 2007..Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine that can induce hyperlipidemia and is known to be modulated by dietary PUFAs... - Prandial glucose regulation in the glucose triad: emerging evidence and insightsPaul Beisswenger
Dartmouth Medical School, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Endocrine 25:195-202. 2004..While more interventional studies clearly are needed, the growing weight of evidence supports a therapeutic approach more directed at excessive prandial glycemic excursions that are characteristic of both type 1 and type 2 diabetes... - Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular riskLuis M Blanco-Colio
Vascular Research Lab Fundación Jimenéz Díaz Autonoma University, Madrid, Spain
Eur J Pharmacol 586:259-65. 2008..In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug... 
Ongoing clinical trials of the pleiotropic effects of statinsJean Davignon
Clinical Research Institute of Montreal, Montreal, QC, Canada
Vasc Health Risk Manag 1:29-40. 2005..The multiple effects (ie, pleiotropic effects of statins) have received increasing recognition and may have clinical applicability across a broad range of cardiovascular and noncardiovascular conditions...- Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified TitrationLuis Miguel Blanco Colio
Vascular Research Laboratory, Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain
Am Heart J 153:881-8. 2007..We analyzed whether treatment with the different doses of atorvastatin affects sICAM-1 and sMCP-1 plasma levels in subjects at high cardiovascular risk... - Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialHenry N Ginsberg
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
Am J Cardiol 99:56i-67i. 2007..The current protocol is designed to provide an ethically justifiable test of combined statin plus fibrate treatment consistent with the highest level of safety and lipid treatment standards of care... - Lipid management in cardiovascular disease prevention guidelines: strategies and tactics for implementationLeif R Erhardt
Department of Cardiology, Malmo University Hospital, Malmo, Sweden
Atherosclerosis 196:532-41. 2008..Include professional societies from different specialties in guideline development and implementation, to increase ownership and decrease fragmentation of guideline committees... - Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesAlice Yy Cheng
Division of Endocrinology and Metabolism, St. Michael's Hospital, Canada
Curr Opin Cardiol 21:400-4. 2006..For individuals with diabetes, recent data support the use of statin therapy, even in those at less than high risk. First-line therapy should remain statins and not fibrates... - How many cardiovascular events can be prevented with optimal management of high-risk Canadians?Daniel T Grima
Cornerstone Research Group Inc, Burlington
Can J Cardiol 24:363-8. 2008.... - Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFASTLuis M Blanco-Colio
Vascular Research Laboratory, Fundacion Jimenez Diaz, Autonoma University, Avenida Reyes Catolicos 2, 28040, Madrid, Spain
Arterioscler Thromb Vasc Biol 27:168-74. 2007..We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment... - Effect of plant sterols in combination with other cholesterol-lowering foodsDavid J A Jenkins
Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, Toronto, Ontario, Canada M5C 2T2
Metabolism 57:130-9. 2008.... - The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyNadia A Khan
Division of General Internal Medicine, University of British Columbia, Vancouver, Canada
Can J Cardiol 24:465-75. 2008..To update the evidence-based recommendations for the prevention and management of hypertension in adults... - The Editor's roundtable: diabetes mellitus and coronary heart diseaseVincent E Friedewald
Internal Medicine, University of Texas Health Sciences Center at Houston, Houston, Texas, USA
Am J Cardiol 98:842-56. 2006 - The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyNadia A Khan
Division of General Internal Medicine, University of British Columbia, Vancouver, British Columbia
Can J Cardiol 23:539-50. 2007..To provide updated, evidence-based recommendations for the prevention and management of hypertension in adults... - The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - TherapyN A Khan
Division of General Internal Medicine, University of British Columbia, Vancouver, BC, Canada
Can J Cardiol 22:583-93. 2006..All recommendations reported here achieved at least 95% consensus. These guidelines will continue to be updated annually... - The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapyNadia A Khan
Division of General Internal Medicine, University of British Columbia, Vancouver, Canada
Can J Cardiol 21:657-72. 2005..All recommendations reported here achieved at least 95% consensus. These guidelines will continue to be updated annually... - Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADESubodh Verma
Eur Heart J 26:1347-9. 2005